×
Back to Agenda
SLS21 “Where, What, and How” of Clinical Trial Information Required by Patients: Disclosure of Investigator Site Name and Clinical Trial Results
Session Chair(s)
Miyoko Yamauchi
Planning & Operation Group, CHUGAI PHARMACEUTICAL CO., LTD., Japan
Speaker(s)
Ryuji Hattori, MPharm
Development Operation, Pfizer Japan Inc., Japan
Kazuyuki Suzuki, MSc
Feasibility Manager,Devlopment SSO protfolio, Novartis Pharma K.K., Japan
Have an account?